Catalyst Capital Advisors’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Catalyst Capital Advisors’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-568	Closed	-$7K	–	505
2019 Q2	$7K	Hold	568	–	–	﹤0.01%	362
2019 Q1	$7K	Buy	+568	New	+$7.64K	﹤0.01%	336

Other funds holding MITO

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Catalyst Capital Advisors's MITO Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2019, closing a stake of 568 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in MITO in Q1 2019 and held it in 2 quarters. The position peaked at $7K in Q2 2019. 7 funds tracked by Wall St. Rank hold MITO as of Q3 2019.

Catalyst Capital Advisors reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2019 after selling out during the quarter.
Catalyst Capital Advisors sold 568 Stealth BioTherapeutics Corp. ADS shares in Q3 2019, an estimated $7K.
Catalyst Capital Advisors first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2019 and held it in 2 quarters.
Catalyst Capital Advisors's Stealth BioTherapeutics Corp. ADS position peaked at $7K in Q2 2019.
7 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.